Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been assigned a consensus rating of “Buy” from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $16.00.

A number of equities analysts recently weighed in on KPTI shares. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Thursday, July 6th. ValuEngine lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 31st. Robert W. Baird reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, July 4th. Royal Bank Of Canada started coverage on shares of Karyopharm Therapeutics in a research note on Thursday, September 14th. They issued an “outperform” rating and a $14.00 target price for the company. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, July 14th.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded up 2.11% during trading on Thursday, hitting $11.62. The stock had a trading volume of 258,997 shares. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63. The stock’s 50 day moving average is $10.66 and its 200 day moving average is $9.90. The stock’s market capitalization is $547.74 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. The business’s revenue for the quarter was down 95.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.84) earnings per share. On average, equities research analysts expect that Karyopharm Therapeutics will post ($2.67) earnings per share for the current fiscal year.

In other news, Director Mansoor Raza Mirza sold 2,882 shares of the stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00. Following the completion of the transaction, the director now directly owns 2,882 shares in the company, valued at approximately $31,702. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last 90 days, insiders have sold 10,695 shares of company stock valued at $118,950. Company insiders own 14.71% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Voya Investment Management LLC boosted its stake in shares of Karyopharm Therapeutics by 42.1% during the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after buying an additional 4,444 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth about $136,000. American International Group Inc. boosted its stake in shares of Karyopharm Therapeutics by 20.9% during the 1st quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after buying an additional 2,836 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth about $202,000. Finally, State of Wisconsin Investment Board acquired a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth about $235,000. Institutional investors own 58.97% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/12/karyopharm-therapeutics-inc-kpti-receives-average-rating-of-buy-from-analysts-2.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.